S23 Results Timeline: What Studies Measured, and When

The short answer: the published timeline for S23 is largely undocumented

Questions phrased as "how long does S23 take to work" or "when do effects appear" assume that a body of timed, published measurements exists. For S23 specifically, the verified citation set behind this page contains no human trial and no indexed time-course experiment, so this page states no onset window, no dose, no effect size and no week-by-week schedule. Stating one anyway would mean inventing numbers, which is exactly what an education page should not do. What follows describes how results timelines are built in published research, what kinds of measurements investigators capture at fixed intervals, why preclinical timelines cannot be read as human timelines, and what evidence would need to appear in the indexed literature before an S23 timeline could be described as documented. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decisions.

What "results timeline" means in the research literature

In published work, a timeline is not a forecast of individual experience. It is a measurement schedule: investigators decide in advance which outcome will be measured, with which instrument, at which timepoints, and in how many subjects. Everything a timeline page can honestly say is therefore downstream of two facts — whether such a schedule was ever run for the compound in question, and whether the results were published in a form that can be located and checked.

The structure is easiest to see in unrelated clinical fields where repeated measurement is routine. Researchers quantitatively compared future liver remnant growth after various portal vein embolization regimens, a design in which the same anatomical measurement is repeated after an intervention so that change can be compared across regimens (PMID 30821547). That is what a timeline is, mechanically: one measurement, defined intervals, a comparison.

Step one: a measurement that has been validated

Before a timeline means anything, the instrument has to be trustworthy. One study assessed hepatic steatosis using ultrasound attenuation imaging with liver biopsy correlation, comparing a non-invasive measurement against a reference standard (PMID 35466506). Without that step, a change observed between two timepoints cannot be separated from the noise of the tool itself.

Step two: agreement between methods used to track change

Timelines also depend on whether two different tools would tell the same story about the same subject. One analysis examined steatosis grading consistency between controlled attenuation parameter and MRI-PDFF when monitoring metabolic associated fatty liver disease (PMID 34408822). The study framed monitoring as an explicit methodological problem rather than an assumption — a useful contrast with informal timelines circulated for unapproved compounds, where the "measurement" is often a self-report with no instrument at all.

Step three: interim timepoints and long-horizon endpoints

Clinical research usually separates interim measurement from outcome measurement. Interim points (commonly weeks 4, 8 and 12 in intervention research) exist to track trajectory and capture safety signals while an intervention is ongoing. Outcome measurement can run far longer: researchers reported steatosis in cirrhosis as a prognostic marker for liver-related outcomes in metabolic-dysfunction associated steatotic liver disease, an endpoint structure that follows subjects toward clinical events rather than short-term changes (PMID 42533609). A compound with no interim data and no long-horizon data has, in effect, no timeline.

The anatomy of a research timeline, generically

None of the studies above involved S23, and none should be read as saying anything about it. They are cited only to show the scaffolding a credible timeline rests on. Read against that scaffolding, the S23 timelines circulated in non-scientific settings are missing all five stages.

Preclinical timelines are not human timelines

When human data are thin, timeline claims often migrate from cell or animal work without being relabeled. That move is worth naming explicitly, because the units of time are not the same. Cell-model research measures molecular endpoints over hours to days: one proteomic analysis examined hormonal contraceptives and depression using neuronal models, generating molecular readouts rather than week-by-week clinical outcomes (PMID 40931400). Animal and mechanistic work similarly reports change on an experimental schedule chosen for the model, as in the study in which researchers reported that a Ling-Gui-Zhu-Gan decoction improved hepatic steatosis through ALKBH1-mediated DNA N(6)-methyladenosine modification (PMID 41237871).

Both designs are legitimate science. Neither supports a statement about what happens in a person at week 4 or week 12. For S23, the honest label is stronger still: the verified set for this page contains no preclinical time-course data either, so there is not even a laboratory schedule to relabel.

Why literature searches for "S23" surface unrelated papers

Alphanumeric compound codes are poor search terms, because the same strings appear as gene names, protein subunits, segment numbers and cohort labels. A search that looks like it returned S23 evidence can easily return work on something else entirely. One paper reported that co-targeting MRPS7-23 synergistically enhanced cisplatin efficacy against nasopharyngeal carcinoma growth and metastasis — a mitochondrial ribosomal protein target, not a selective androgen receptor modulator (PMID 41522354). Numeric labels collide in surgical anatomy too, as in the study examining the importance of Segment 4 anatomy on outcomes following living donor left lateral segmentectomy (PMID 36638550).

The practical consequence is that a timeline page assembled by pattern-matching on the string "S23" can look well cited while citing nothing relevant. Checking that each reference actually concerns the compound named in the heading is the first filter any reader can apply.

Adverse Events and Timelines: What Studies Report

The verified literature behind this page contains no adverse-event data for S23 — no incidence figures, no onset intervals, no reversibility data, and no laboratory monitoring schedule. That absence is the finding, and it is not the same as a finding of safety. Where a compound has not been studied in humans in the indexed literature, the frequency and timing of harms are unknown rather than low.

For context on how adverse events are captured when studies do exist: safety data come from the same scheduled visits that generate efficacy data, which is why monitoring methodology matters as much as endpoint choice, as in the comparison of steatosis grading consistency between two modalities during follow-up (PMID 34408822), and why validation against a reference standard precedes routine use of a measurement (PMID 35466506). Informal timelines for unapproved compounds have neither scheduled visits nor validated instruments.

On regulatory status: S23 is not an approved medicine in the United States, there is no approved product label describing its onset, duration or adverse-event profile, and material distributed under that name is typically labeled research-use-only and not intended for human consumption. Selective androgen receptor modulators as a class are also prohibited in competitive sport under anti-doping rules. These are regulatory facts, not an assessment of effect.

What would have to exist for an S23 timeline to be evidence-based

1. A validated outcome measure — a defined endpoint and an instrument shown to track it, as validation studies do against reference standards (PMID 35466506).
2. A stated baseline in a defined population, so later values have a comparator (PMID 30821547).
3. Pre-specified timepoints rather than measurements taken whenever a change was noticed.
4. A control or comparison arm, as in the quantitative comparison across embolization regimens (PMID 30821547).
5. Safety capture at each visit, using methods whose consistency has itself been examined (PMID 34408822).
6. Long-horizon outcomes, because short-term change does not automatically predict clinical events (PMID 42533609).

Measured against that list, "week 1 to 2," "week 4 to 6" and "week 8 to 12" schedules attached to S23 in non-scientific settings are anecdote arranged chronologically. Chronological arrangement is not measurement.

Reading timeline claims critically

• Check the subject of every citation. If a reference concerns a gene subunit or a surgical segment, it is not S23 evidence (PMID 41522354, PMID 36638550).
• Check the species and model. Cell-model proteomics answers molecular questions, not human-week questions (PMID 40931400).
• Check whether anything was measured at all, and with what instrument.
• Treat missing data as missing, not as reassurance.

Related reading

For background on what the compound is, how it is classified and what the indexed record does and does not contain, see the PeptideU overview page at /learn/s23/.

References

• Future liver remnant growth after various portal vein embolization regimens: a quantitative comparison (Minimally Invasive Therapy & Allied Technologies, 2020)
• Hepatic steatosis: Ultrasound assessment using attenuation imaging (ATI) with liver biopsy correlation (Journal of Medical Imaging and Radiation Oncology, 2023)
• Steatosis grading consistency between controlled attenuation parameter and MRI-PDFF in monitoring metabolic associated fatty liver disease (Therapeutic Advances in Chronic Disease, 2021)
• Steatosis in Cirrhosis: A Prognostic Marker for Liver-Related Outcomes in Metabolic-Dysfunction Associated Steatotic Liver Disease (Liver International, 2026)
• Ling-Gui-Zhu-Gan decoction improves hepatic steatosis through ALKBH1-mediated DNA N(6)-methyladenosine modification (Journal of Ethnopharmacology, 2026)
• Hormonal Contraceptives and Depression: A Proteomic Analysis Using Neuronal Models (Proteomics. Clinical Applications, 2026)
• Co-targeting MRPS7-23 synergistically enhances cisplatin efficacy to suppress nasopharyngeal carcinoma growth and metastasis (International Journal of Biological Sciences, 2026)
• The Importance of Segment 4 Anatomy on Outcomes Following Living Donor Left Lateral Segmentectomy (Journal of Surgical Research, 2023)